In short
Clinical trials are investigating Vamorolone in boys with Duchenne Muscular Dystrophy (DMD). These studies aim to learn about long-term safety and how well treatment works over time. The trial data here focus on children who have already taken part in earlier Vamorolone studies.
Key points
- Clinical trial data for Vamorolone focus on boys with Duchenne Muscular Dystrophy. The study is an open-label, Phase 3 trial called the GUARDIAN Study. It is designed to collect long-term safety and effectiveness information in patients who already completed earlier Vamorolone studies. The main outcome is the number of vertebral fractures per 1000 person-years, checked by central X-ray reading. The trial is authorised and plans to enroll 65 participants.
Trial overview
The available clinical trial is an open-label study of Vamorolone in boys with Duchenne Muscular Dystrophy (DMD). It is designed to collect information on long-term treatment, with a focus on both safety and effectiveness.
The trial is interventional, which means the researchers are giving a treatment and then observing what happens during the study. The study is authorised and plans to enroll 65 participants.
Who can participate
This study is for boys with Duchenne Muscular Dystrophy who have already completed prior studies with Vamorolone. This makes the trial a follow-up study for a specific group of patients who have taken part in earlier research.
Because the trial is focused on long-term follow-up, the participants are not a general DMD group, but a selected group with prior Vamorolone study experience.
Study design and phase
The study is in Phase 3. Phase 3 studies usually involve more participants than early trials and help researchers learn more about how well a treatment works and how safe it is in a broader group.
Because this is an open-label trial, there is no blinding in the study data provided. In simple terms, the treatment is known during the study rather than hidden from participants and researchers.
What is being measured
The main outcome is the number of vertebral fractures per 1000 person-years, based on X-ray central reading. Vertebral fractures are breaks in the bones of the spine, and central reading means experts review the X-rays using the same method for all participants.
This endpoint shows that the study is especially interested in bone safety during long-term treatment. The brief study summary also says the goal is to evaluate safety of long-term treatment with Vamorolone in boys with DMD regarding vertebral fractures.
The GUARDIAN Study
The trial title names it as the GUARDIAN Study. It is an open-label study to collect safety and effectiveness information on long-term treatment with Vamorolone in boys with DMD who have completed prior studies with Vamorolone.
In patient terms, this means the study is following children over time to see how they do after earlier Vamorolone research. The main focus is not a new comparison with another drug, but ongoing monitoring of outcomes during continued treatment.